Buy Eikon Therapeutics stock | $EIKN Share Price

13:30

15:10

16:45

18:25

20:00

About Eikon Therapeutics

Eikon Therapeutics Inc is a late-stage clinical biopharmaceutical company dedicated to building a world-wide , fully-integrated organization developing important, medicines to address serious unmet medical needs. It operates in a single operating segment, which is in the business of drug discovery leveraging its proprietary technology and clinical development of its product candidates. Its product candidates include: EIK1001, EIK1003, EIK1004, EIK1005, and EIK1006.

Ticker

$EIKN

Sector

Health

Primary listing

NASDAQ

Employees

Headquarters

Millbrae, United States

Website

eikontx.com

EIKN Metrics

BasicAdvanced

$638M

-$113.67

What the Analysts think about EIKN

Analyst ratings (Buy, Hold, Sell) for Eikon Therapeutics stock.

Bulls say / Bears say

Raised $381.2 million in an upsized IPO, selling 21.2 million shares at the top of the marketed range, securing major funding for its clinical-stage oncology pipeline (Reuters).

Led by CEO Roger Perlmutter, former Merck research head known for Keytruda’s success, boosting credibility with investors and industry partners (Reuters).

Its lead candidate EIK1001 is in a Phase 2/3 trial combined with pembrolizumab, with interim results expected in the second half of 2026, offering a clear near-term catalyst (Reuters).

Shares began trading at $17.05, 5.3% below the $18 IPO price, reflecting weak investor interest at its Nasdaq debut (Reuters).

The debut valuation of around $860.3 million was below the pre-IPO target of up to $908.2 million, pointing to pricing pressure and cautious investor sentiment (Reuters).

The TLR7/8 agonist drug class, including its lead asset EIK1001, has a track record of systemic toxicity issues, presenting a significant safety risk for its clinical program (Reuters).

Data summarised monthly by Lightyear AI. Last updated on 14 Mar 2026.

EIKN Financial Performance

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37B

-39.75%

Net income

$45B

107.52%

Profit margin

37.65%

6.78%

EIKN Earnings Performance

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $EIKN

Capital at risk

Market open

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Eikon Therapeutics stock?

Eikon Therapeutics (EIKN) has a market cap of $638M as of March 23, 2026.

What is the P/E ratio for Eikon Therapeutics stock?

The price to earnings (P/E) ratio for Eikon Therapeutics (EIKN) stock is 0 as of March 23, 2026.

Does Eikon Therapeutics stock pay dividends?

No, Eikon Therapeutics (EIKN) stock does not pay dividends to its shareholders as of March 23, 2026.

When is the next Eikon Therapeutics dividend payment date?

Eikon Therapeutics (EIKN) stock does not pay dividends to its shareholders.

What is the beta indicator for Eikon Therapeutics?

Eikon Therapeutics (EIKN) does not currently have a Beta indicator.

Bulls say / Bears say

Raised $381.2 million in an upsized IPO, selling 21.2 million shares at the top of the marketed range, securing major funding for its clinical-stage oncology pipeline (Reuters).

Led by CEO Roger Perlmutter, former Merck research head known for Keytruda’s success, boosting credibility with investors and industry partners (Reuters).

Its lead candidate EIK1001 is in a Phase 2/3 trial combined with pembrolizumab, with interim results expected in the second half of 2026, offering a clear near-term catalyst (Reuters).

Shares began trading at $17.05, 5.3% below the $18 IPO price, reflecting weak investor interest at its Nasdaq debut (Reuters).

The debut valuation of around $860.3 million was below the pre-IPO target of up to $908.2 million, pointing to pricing pressure and cautious investor sentiment (Reuters).

The TLR7/8 agonist drug class, including its lead asset EIK1001, has a track record of systemic toxicity issues, presenting a significant safety risk for its clinical program (Reuters).

Data summarised monthly by Lightyear AI. Last updated on 14 Mar 2026.

About Eikon Therapeutics

Ticker

Employees

EIKN Metrics

Price and volume

Financial strength

Profitability

Management effectiveness

Valuation

Growth

What the Analysts think about EIKN

Analyst Ratings

Bulls say / Bears say

EIKN Financial Performance

Income Statement

EIKN Earnings Performance

Earnings per share (EPS)

EIKN News

Eikon Therapeutics valued at $860 million in Nasdaq debut

Buy $EIKN

Upcoming events

No upcoming events

What’s the current market cap for Eikon Therapeutics stock?

What is the P/E ratio for Eikon Therapeutics stock?

Does Eikon Therapeutics stock pay dividends?

When is the next Eikon Therapeutics dividend payment date?

What is the beta indicator for Eikon Therapeutics?

Lightyear

Legal

Work with us

Bulls say / Bears say

Eikon Therapeutics/$EIKN

About Eikon Therapeutics

Ticker

Employees

EIKN Metrics

Price and volume

Financial strength

Profitability

Management effectiveness

Valuation

Growth

What the Analysts think about EIKN

Analyst Ratings

Bulls say / Bears say

EIKN Financial Performance

Income Statement

EIKN Earnings Performance

Earnings per share (EPS)

EIKN News

Eikon Therapeutics valued at $860 million in Nasdaq debut

Buy $EIKN

Upcoming events

No upcoming events

What’s the current market cap for Eikon Therapeutics stock?

What is the P/E ratio for Eikon Therapeutics stock?

Does Eikon Therapeutics stock pay dividends?

When is the next Eikon Therapeutics dividend payment date?

What is the beta indicator for Eikon Therapeutics?

Bulls say / Bears say